Phase 1 trial now testing 2 new QRL-201 doses in ALS patients - ALS News Today
The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.
Search Group
Share To
Comments
About Screade
Screade® Inc. version f7eb701, copyright 2016 - 2025
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments